156 related articles for article (PubMed ID: 7825805)
41. Alterations of pineal gland and of T lymphocyte subsets in metastatic cancer patients: preliminary results.
Lissoni P; Tancini G; Barni S; Viviani S; Archili C; Cattaneo G; Fiorelli G
J Biol Regul Homeost Agents; 1989; 3(4):181-3. PubMed ID: 2534688
[TBL] [Abstract][Full Text] [Related]
42. In vitro modulatory effects of interleukin-3 on macrophage activation induced by interleukin-2.
Lissoni P; Pittalis S; Brivio F; Tisi E; Rovelli F; Ardizzoia A; Barni S; Tancini G; Giudici G; Biondi A
Cancer; 1993 Mar; 71(6):2076-81. PubMed ID: 8443757
[TBL] [Abstract][Full Text] [Related]
43. Efficacy and tolerability of cancer neuroimmunotherapy with subcutaneous low-dose interleukin-2 and the pineal hormone melatonin - a progress report of 200 patients with advanced solid neoplasms.
Lissoni P; Ardizzoia A; Barni S; Brivio F; Tisi E; Rovelli F; Tancini G; Maestroni G; Fumagalli L
Oncol Rep; 1995 Nov; 2(6):1063-8. PubMed ID: 21597854
[TBL] [Abstract][Full Text] [Related]
44. A study of immunoendocrine strategies with pineal indoles and interleukin-2 to prevent radiotherapy-induced lymphocytopenia in cancer patients.
Lissoni P; Rovelli F; Brivio F; Fumagalli L; Brera G
In Vivo; 2008; 22(3):397-400. PubMed ID: 18610754
[TBL] [Abstract][Full Text] [Related]
45. Modulation of macrophage response to interleukin-2 immunotherapy by interleukin-3 in cancer patients.
Lissoni P; Rovelli F; Barni S; Ardizzoia A; Pittalis S; Tisi E; Perlangeli V; Tancini G
Biol Chem Hoppe Seyler; 1992 Dec; 373(12):1217-22. PubMed ID: 1292506
[TBL] [Abstract][Full Text] [Related]
46. Treatment of cancer chemotherapy-induced toxicity with the pineal hormone melatonin.
Lissoni P; Tancini G; Barni S; Paolorossi F; Ardizzoia A; Conti A; Maestroni G
Support Care Cancer; 1997 Mar; 5(2):126-9. PubMed ID: 9069612
[TBL] [Abstract][Full Text] [Related]
47. Biochemotherapy with standard chemotherapies plus the pineal hormone melatonin in the treatment of advanced solid neoplasms.
Lissoni P
Pathol Biol (Paris); 2007; 55(3-4):201-4. PubMed ID: 17446010
[TBL] [Abstract][Full Text] [Related]
48. Therapeutic potential of melatonin in immunodeficiency states, viral diseases, and cancer.
Maestroni GJ
Adv Exp Med Biol; 1999; 467():217-26. PubMed ID: 10721059
[TBL] [Abstract][Full Text] [Related]
49. A phase II study of chemoneuroimmunotherapy with platinum, subcutaneous low-dose interleukin-2 and the pineal neurohormone melatonin (P.I.M.) as a second-line therapy in metastatic melanoma patients progressing on dacarbazine plus interferon-alpha.
Lissoni P; Vaghi M; Ardizzoia A; Malugani F; Fumagalli E; Bordin V; Fumagalli L; Bordoni A; Mengo S; Gardani GS; Tancini G
In Vivo; 2002; 16(2):93-6. PubMed ID: 12073777
[TBL] [Abstract][Full Text] [Related]
50. Treatment of cancer-related thrombocytopenia by low-dose subcutaneous interleukin-2 plus the pineal hormone melatonin: a biological phase II study.
Lissoni P; Barni S; Brivio F; Rossini F; Fumagalli L; Tancini G
J Biol Regul Homeost Agents; 1995; 9(2):52-4. PubMed ID: 9127633
[TBL] [Abstract][Full Text] [Related]
51. The pineal gland as a central regulator of cytokine network.
Lissoni P
Neuro Endocrinol Lett; 1999; 20(6):343-349. PubMed ID: 11458197
[TBL] [Abstract][Full Text] [Related]
52. Melatonin protects mice against stress-induced inflammation through enhancement of M2 macrophage polarization.
Yi WJ; Kim TS
Int Immunopharmacol; 2017 Jul; 48():146-158. PubMed ID: 28505494
[TBL] [Abstract][Full Text] [Related]
53. A randomized study of neuroimmunotherapy with low-dose subcutaneous interleukin-2 plus melatonin compared to supportive care alone in patients with untreatable metastatic solid tumour.
Lissoni P; Barni S; Fossati V; Ardizzoia A; Cazzaniga M; Tancini G; Frigerio F
Support Care Cancer; 1995 May; 3(3):194-7. PubMed ID: 7655780
[TBL] [Abstract][Full Text] [Related]
54. Preoperative neuroimmunotherapy with subcutaneons low-dose interleukin-2 and melatonin in patients with gastrointestinal tumors - its efficacy in preventing surgery-induced lymphocytopenia.
Brivio F; Lissoni P; Fumagalli L; Brivio O; Lavorato F; Rescaldani R; Conti A; Roselli M; Maestroni G; Barni S
Oncol Rep; 1995 Jul; 2(4):597-9. PubMed ID: 21597783
[TBL] [Abstract][Full Text] [Related]
55. Is there a role for melatonin in supportive care?
Lissoni P
Support Care Cancer; 2002 Mar; 10(2):110-6. PubMed ID: 11862501
[TBL] [Abstract][Full Text] [Related]
56. Normalization of the light/dark rhythm of melatonin after prolonged subcutaneous administration of interleukin-2 in advanced small cell lung cancer patients.
Viviani S; Bidoli P; Spinazzé S; Rovelli F; Lissoni P
J Pineal Res; 1992 Apr; 12(3):114-7. PubMed ID: 1324306
[TBL] [Abstract][Full Text] [Related]
57. [Effect of melatonin on the activation and proliferation of neonatal cord blood mononuclear cell].
Wang P; Zhou W; Tao L
Zhonghua Er Ke Za Zhi; 2007 Jul; 45(7):529-32. PubMed ID: 17953811
[TBL] [Abstract][Full Text] [Related]
58. Prevention of cytokine-induced hypotension in cancer patients by the pineal hormone melatonin.
Lissoni P; Pittalis S; Ardizzoia A; Brivio F; Barni S; Tancini G; Pelizzoni F; Maestroni GJ; Zubelewicz B; Braczkowski R
Support Care Cancer; 1996 Jul; 4(4):313-6. PubMed ID: 8829312
[TBL] [Abstract][Full Text] [Related]
59. Psychoneuroendocrine modulation of regulatory T lymphocyte system: in vivo and in vitro effects of the pineal immunomodulating hormone melatonin.
Vigoré L; Messina G; Brivio F; Fumagalli L; Rovelli F; DI Fede G; Lissoni P
In Vivo; 2010; 24(5):787-9. PubMed ID: 20952751
[TBL] [Abstract][Full Text] [Related]
60. Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status.
Lissoni P; Barni S; Mandalà M; Ardizzoia A; Paolorossi F; Vaghi M; Longarini R; Malugani F; Tancini G
Eur J Cancer; 1999 Nov; 35(12):1688-92. PubMed ID: 10674014
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
